Support Line: 0800 002 9002
General Enquiries: 01223 870008
Donate

News Archive

Ipilimumab

Cabo + nivo & ipi delays kidney cancer progression

Cabo + nivo & ipi delays kidney cancer progression

Cabozantinib| Ipilimumab| Nivolumab
Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
Kidney Cancer UK represents patients at NICE nivo+ipi appraisal

Kidney Cancer UK represents patients at NICE nivo+ipi appraisal

Ipilimumab| NICE| Nivolumab
On 3rd February 2022, NICE approve the use of nivolumab with ipilimumab as a first line treatment for kidney ...
SMC Recommend nivolumab + ipilimumab for 1st line Rcc

SMC Recommend nivolumab + ipilimumab for 1st line Rcc

Ipilimumab| Nivolumab
By: Maureen Johnson - RGN, BSc (hons) Physiology Kidney Cancer Scotland and Northern Ireland Health ...
NICE recommend nivolumab + ipilimumab combo through CDF

NICE recommend nivolumab + ipilimumab combo through CDF

Ipilimumab| NICE| Nivolumab
  Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has ...
European Commission approves nivolumab ipilimumab combo

European Commission approves nivolumab ipilimumab combo

Ipilimumab| Nivolumab
The European Commission has approved nivolumab in combination with low-dose ipilimumab for first-line treatment of ...
CHMP adopts a positive opinion of nivolumab + ipilimumab as 1st line treatment

CHMP adopts a positive opinion of nivolumab + ipilimumab as 1st line treatment

Ipilimumab| Nivolumab
Press release: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) ...
kidney cancer drug test stopped after early success

kidney cancer drug test stopped after early success

Ipilimumab| Nivolumab| Opdivo| Yervoy
(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall ...